Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Cellenkos, Inc.
Primary Objective: To determine dose-limiting toxicity of CK0801 as defined as any of the events each start at the time of CK00801 infusion 1. Severe (grade 3 or 4) infusion toxicity within 24 hours (NCI-CTCAE V4.0) 2. Regimen related death within 30 days 3. Severe (grade 3 or 4) Cytokine Release Syndrome within 30 days Secondary Objective: 1. Preliminary assessment of disease-specific response 2. Duration of disease-specific response
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted